خانه › سندرم‌های میلودیسپلاستیک › تگزاس › Houston
آزمایش‌های بالینی سندرم‌های میلودیسپلاستیک در Houston، TX
43 مطالعه برای سندرم‌های میلودیسپلاستیک در مراکز Houston (در شعاع حدود ۳۰ مایل) در جستجوی شرکت‌کننده هستند. یک مطالعه را باز کنید تا شرایط شرکت و نحوه تماس با تیم پژوهشی را ببینید.
متن رسمی مطالعه (انگلیسی)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
در حال جذب شرکت‌کنندهمرحله 1
- University of Texas MD Anderson Cancer Center, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
در حال جذب شرکت‌کنندهمرحله 1/2
- MD Anderson Cancer Center, Houston
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
در حال جذب شرکت‌کنندهمرحله 1/2
- M D Anderson Cancer Center, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
در حال جذب شرکت‌کنندهمرحله 1/2
- MD Anderson, Houston
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
در حال جذب شرکت‌کنندهمرحله 3
- The University of Texas-MD Anderson Cancer Center - Leukemia Center, Houston
- LUMI Research, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
در حال جذب شرکت‌کنندهمرحله 1
- M D Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
در حال جذب شرکت‌کنندهمرحله 1/2
- M D Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
در حال جذب شرکت‌کنندهمرحله 2
- M D Anderson Cancer Center, Houston
A Study of BGB-11417 in Participants With Myeloid Malignancies
در حال جذب شرکت‌کنندهمرحله 1/2
- Md Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
در حال جذب شرکت‌کنندهمرحله 2پذیرش داوطلبان سالم
- MD Anderson Cancer Center, Houston
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
در حال جذب شرکت‌کنندهمرحله 1
- The University of Texas MD Anderson Cancer Center, Houston
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
در حال جذب شرکت‌کنندهمرحله 1/2
- M D Anderson Cancer Center, Houston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
در حال جذب شرکت‌کنندهمرحله 3
- MD Anderson Cancer Centre, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
در حال جذب شرکت‌کنندهمرحله 2
- M D Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
در حال جذب شرکت‌کنندهمرحله 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
در حال جذب شرکت‌کنندهمرحله 3
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
در حال جذب شرکت‌کنندهمرحله 2
- Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
در حال جذب شرکت‌کنندهمرحله 2/3پذیرش داوطلبان سالم
- M D Anderson Cancer Center, Houston
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
در حال جذب شرکت‌کنندهمرحله 1/2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
در حال جذب شرکت‌کنندهمرحله 1/2
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
در حال جذب شرکت‌کنندهمرحله 2
- M D Anderson Cancer Center, Houston
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
در حال جذب شرکت‌کنندهمرحله 1/2
- Research Site, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
در حال جذب شرکت‌کنندهمرحله 2
- University of Texas MD Anderson Cancer Center, Houston
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
در حال جذب شرکت‌کنندهمرحله 2
- M D Anderson Cancer Center, Houston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
در حال جذب شرکت‌کنندهمرحله 1
- MD Anderson Cancer Center, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
در حال جذب شرکت‌کنندهمرحله 1
- MD Anderson Cancer Center, Houston
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
در حال جذب شرکت‌کنندهمرحله 2
- M D Anderson Cancer Center, Houston
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
در حال جذب شرکت‌کنندهمرحله 2
- GSK Investigational Site, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
در حال جذب شرکت‌کنندهمرحله 1
- MD Anderson, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
در حال جذب شرکت‌کنندهمرحله 1
- MD Anderson, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
در حال جذب شرکت‌کنندهمرحله 2
- M D Anderson Cancer Center, Houston
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
در حال جذب شرکت‌کنندهمرحله 2
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
در حال جذب شرکت‌کنندهمرحله 2/3
- MD Anderson Cancer Center, Houston
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
در حال جذب شرکت‌کنندهمرحله 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
در حال جذب شرکت‌کنندهمرحله 1
- MD Anderson Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
در حال جذب شرکت‌کنندهمرحله 1/2
- MDACC, Houston
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
در حال جذب شرکت‌کنندهمرحله 1
- MD Anderson, Houston
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
در حال جذب شرکت‌کنندهمرحله 1پذیرش داوطلبان سالم
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
در حال جذب شرکت‌کنندهمرحله 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of REM-422 in Patients With AML or Higher Risk MDS
در حال جذب شرکت‌کنندهمرحله 1
- MD Anderson Cancer Center, Houston
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
در حال جذب شرکت‌کنندهمرحله 1
- The University of Texas MD Anderson Cancer Center, Houston
آزمایش‌های سندرم‌های میلودیسپلاستیک در سایر شهرها
- Baldwin Park, CA26 مطالعه
- New York City, NY21 مطالعه
- Seattle, WA21 مطالعه
- Washington, DC20 مطالعه
- Boston, MA19 مطالعه
- Tampa, FL19 مطالعه
- Miami, FL17 مطالعه
- Columbus, OH14 مطالعه
- Durham, NC14 مطالعه
- Chicago, IL13 مطالعه
- Atlanta, GA13 مطالعه
- St. Louis, MO13 مطالعه
سایر مطالعات در Houston
- سرطان ریه غیرسلول کوچک145 مطالعه
- سرطان پستان126 مطالعه
- سرطان (همه انواع)121 مطالعه
- سرطان متاستاتیک104 مطالعه
- سرطان کولورکتال102 مطالعه
- سرطان تخمدان89 مطالعه
- لوکمیه حاد میلویید85 مطالعه
- سرطان ریه78 مطالعه
- سرطان پروستات76 مطالعه
- سرطان آندومتر68 مطالعه
- سرطان لوزالمعده61 مطالعه
- ملانوم59 مطالعه
از ClinicalTrials.gov، داده‌ها در تاریخ 5 اکتبر 2026 دریافت شده است. هر مطالعه شرایط اختصاصی خود را دارد؛ تیم پژوهشی تصمیم می‌گیرد چه کسانی می‌توانند شرکت کنند.